Pharmafile Logo
Pharmafocus logo
Advanced Search
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10

News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …

News

Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

February 15, 2019
Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …

News

AstraZeneca to retire MedImmune brand amid restructuring

February 15, 2019
Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …

News

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019
Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …

News
shutterstock_232245868

First asthma pill in two decades could treat condition by reducing airway muscle

February 14, 2019
Research and Development asthma, pharma

Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …

News
takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News

FDA approves Novartis’ Egaten for parasitic infection fascioliasis

February 14, 2019
Sales and Marketing Egaten, FDA, Novartis, fascioliasis, pharma

The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …

News
shutterstock_138095450

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

February 14, 2019
Sales and Marketing Clinigen, Novartis, Proleukin, pharma

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant …

News

J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal

February 14, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics

In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …

News

BMS scores expanded European approval for Sprycel in paediatric leukaemia

February 13, 2019
Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma

Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …

News
cannabis-2152604_960_720

Australian firm Althea enters UK medicinal cannabis market

February 13, 2019
Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis

Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …

News
janssen_latest_logo_on_sign_closer

Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …

News
101817_tumorsmyeloidsuppressorcells

Researchers find new type of cell membrane which causes cancer cells to explode

February 13, 2019
Research and Development Cancer, FTY720, cell membranes, molecules, oncology

Researchers at the Medical University of South Carolina (MUSC) have discovered a new type of cell membrane complex which causes …

News
image_credit_-_rafael_matsunaga

Clinigen shares soar after $210m Novartis cancer drug deal

February 13, 2019
Research and Development Cancer, Clinigen, Novartis, Proleukin, UK, US, oncology

British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal …

News
dr_nathwani_770x510

Sanofi name current CMO Dr Ameet Nathwani as new Chief Digital Officer

February 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

French firm Sanofi has appointed pharma veteran Dr Ameet Nathwani to the position of Chief Digital Officer. In his new …

Appointment
scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
guernsey-1881254_960_720

Immuno Biotech financial chief found guilty of money laundering

February 12, 2019
Manufacturing and Production David Noakes, Dawson-Ball, GcMAF, Guernsey, Immuno Biotech

Peter Edward Dawson-Ball, the financial head of the Guernsey-based firm immuno Biotech, that sold unlicensed blood product GcMAF, has been …

News
merck-keytruda

Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma

February 12, 2019
Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …

News
5204602349_c87b204860_z

FDA to crack down on dietary supplements

February 12, 2019
Manufacturing and Production Alzheimer's, Alzheimers, Cancer, Dietary Supplements, FDA, USA, diabetes

The FDA is cracking down on those selling ‘dietary supplements’, having sent warning letters to companies who claim, without proof, …

News
gilead-sciences

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …

News
The Gateway to Local Adoption Series

Latest content

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026